Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J2781) for SYFOVRE® (pegcetacoplan injection), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code for SYFOVRE will become effective on October 1, 2023.
"Until SYFOVRE, patients had nothing to slow the progression of this relentless and irreversible disease,” said Adam Townsend, chief commercial officer, Apellis. “The permanent J-code is a significant milestone that will help ensure accurate and efficient reimbursement of SYFOVRE in all treatment settings, building on our goal of bringing this important treatment to GA patients in need.”
J-codes are permanent reimbursement codes used by government payers and commercial insurers to facilitate billing of Medicare Part B treatments, which must be administered by a healthcare professional. J-codes simplify and streamline the billing and reimbursement processes, allowing for efficient claims processing.
The permanent J-code has been published by CMS here.
About Geographic Atrophy (GA)
About SYFOVRE® (pegcetacoplan injection)
U.S. Important Safety Information for SYFOVRE® (pegcetacoplan injection)
WARNINGS AND PRECAUTIONS
Please see accompanying full Prescribing Information for more information.
Apellis Forward-Looking Statement
1 Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta analysis. Ophthalmology 2012;119:571–580.
The Metaverse - It is Real: a Year in Review
Monetizing the Coming Wave of Innovation Around Generative AI
Solutions Showcase Session